Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Sarah E. Donegan"'
Autor:
Stephan Hois, Feng Xiao, Sarah E. Donegan, Hiroyuki Nishiyama, Matthew D. Galsky, Erik T. Goluboff, Joshua J. Meeks, Hikmat Al-Ahmadie, Vanessa Williams, Michiel S. van der Heijden, James W.F. Catto, Thomas Powles
Publikováno v:
Journal of Clinical Oncology. 39:TPS505-TPS505
TPS505 Background: Management of muscle-invasive bladder cancer (MIBC) includes both surgery and systemic therapy. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated improved pathologic complete response (pCR), event-free survival
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef58280fe5862083a3a7bcbfba99ff00
https://doi.org/10.1200/jco.2021.39.6_suppl.tps505
https://doi.org/10.1200/jco.2021.39.6_suppl.tps505
Autor:
Thomas Powles, Joshua J Meeks, Matt D. Galsky, Michiel Simon Van Der Heijden, Hiroyuki Nishiyama, Hikmat Al-Ahmadie, Ashok Kumar Gupta, Jiabu Ye, Sarah E. Donegan, Dana C. Ghiorghiu, Salvatore Ferro, James WF Catto
Publikováno v:
Journal of Clinical Oncology. 37:TPS4592-TPS4592
TPS4592 Background: Management of MIBC includes both surgery and systemic therapy. Neoadjuvant, cisplatin-based combination chemotherapy has demonstrated improved pathologic complete response (pCR), event-free survival (EFS), and OS compared with rad
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e06a9354fe53c9b77739bd5738002245
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4592
https://doi.org/10.1200/jco.2019.37.15_suppl.tps4592
Autor:
Sarah E. Donegan
Publikováno v:
Journal of Oncology Pharmacy Practice. 6:153-165
Objective. To provide an overview of the proposed pathophysiology of ifosfamide encephalopathy and the role of methylene blue for the treatment and prevention of this toxicity. Data Source. A Medline search using the terms ‘‘ifosfamide encephalop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cbe6d835308602bb327d972994524e0
https://doi.org/10.1177/107815520100600404
https://doi.org/10.1177/107815520100600404
Autor:
Brendan D. Curti, Walter J. Urba, Barry L. Gause, John E. Janik, Edward L. Korn, Sarah E. Donegan, Langdon L. Miller, John W. Smith, Dan L. Longo, Thelma M. Watson, Diane Stevens, Mario Sznol, William C. Kopp, Jon Holmlund
Publikováno v:
Blood. 93:3250-3258
This dose-escalation study was performed to evaluate the hematologic activity, biological effects, immunogenicity, and toxicity of PIXY321 (an interleukin-3/granulocyte-macrophage colony-stimulating factor fusion protein) administered after high-dose
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b11eb8a44c25458183b818a74b08604f
https://doi.org/10.1182/blood.v93.10.3250.410k35_3250_3258
https://doi.org/10.1182/blood.v93.10.3250.410k35_3250_3258
Autor:
Karen M. Naples, Sarah E. Donegan
Publikováno v:
Cancer practice. 10(1)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5482155c06c6df0dad42762673d4924
https://pubmed.ncbi.nlm.nih.gov/11866711
https://pubmed.ncbi.nlm.nih.gov/11866711
Autor:
William C. Kopp, Paige Kostboth, Dan L. Longo, Diane Stevens, Barry L. Gause, Sarah E. Donegan, Brendan D. Curti, Langdon L. Miller, Robert Ullrich, Dennis D. Taub, Harry D. Dawson, John E. Janik, Barbara K. Dunn, Kevin C. Conlon, W. Gregory Alvord
Publikováno v:
Clinical immunology (Orlando, Fla.). 93(3)
Dendritic cells (DCs) initiate primary and stimulate secondary T-cell responses. We conducted a phase I trial of tumor necrosis factor (TNF-alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with cancer to increase DCs i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2493bfeaec839e4c78dd0ac5e83afd05
https://pubmed.ncbi.nlm.nih.gov/10600331
https://pubmed.ncbi.nlm.nih.gov/10600331
Autor:
John C. Byrd, Thomas J. Maneatis, Frank T. Ward, Sarah E. Donegan, Timothy Murphy, Melissa A. Sipe, Brian P. Monahan, Christine A. White, Jamie K. Waselenko
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 17(3)
PURPOSE: Rituximab was recently approved for use in relapsed, low-grade non-Hodgkin's lymphoma; however, few data exist regarding the safety of this agent in patients with a high number of tumor cells in the blood. METHODS AND RESULTS: After the obse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e124029e421d2aa361f467aa49edc882
https://pubmed.ncbi.nlm.nih.gov/10071268
https://pubmed.ncbi.nlm.nih.gov/10071268
Publikováno v:
Cancer Practice. Jan2002, Vol. 10 Issue 1, pi. 1p.
Autor:
Donegan, Sarah E1, Naples, Karen M2
Publikováno v:
Cancer Practice. Jan2002, Vol. 10 Issue 1, p53-56. 4p.
Drug-Induced Diseases: Prevention, Detection, and Management : Prevention, Detection, and Management
Autor:
James E. Tisdale, Douglas A, Miller
According to the authors, a drug-induced disease as an unintended effect of a drug, which results in mortality or morbidity with symptoms sufficient to prompt a patient to seek medical attention and/or require hospitalization. Since the first edition
